Key result
Genetic markers influence patient response to major antithrombotics including aspirin, warfarin, P2Y12 inhibitors, and DOACs.
Why the study?
How do genetic markers influence individual variability in drug response to antithrombotic agents?
How do genetic markers influence individual variability in drug response to antithrombotic agents?
This review highlights the role of pharmacogenetics in predicting individual responses, efficacy, and bleeding risks associated with commonly used antithrombotic drugs.
May inform personalized antithrombotic selection; leaves open prospective trials before clinical adoption.
The review deals with the main trials devoted to the study of genetic markers of individual variability in drug response to antithrombotic agents. The first part describes the studies of the genes encoding the platelet receptor subunits studied in the association of the possible insufficient effect of acetylsalicylic acid, and transporter proteins and allelic variants with reduced CYP450 functional activity, which are associated with insufficient effect on clopidogrel therapy. The second part considers polymorphisms that determine the individual dose and the risk of bleeding due to excessive hypocoagulation in patients taking warfarin. It also presents current data on the study of genetically determined individual reactions to the new inhibitors: P2Y12 inhibitors (prasugrel and ticagrelor) and direct oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Е. С. Кропачева (2018) conducted a review in Patients taking antithrombotic agents. Antithrombotic drugs was evaluated. Genetic markers of individual variability influence drug response to antithrombotic agents, including acetylsalicylic acid, clopidogrel, warfarin, P2Y12 inhibitors, and direct oral anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: